{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:01:19Z","timestamp":1793822479962,"version":"4.6.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3014,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Early identification of patients with severe (discriminant function \u2265 32) alcoholic hepatitis (AH) not responding to corticosteroids is crucial. We generated a specific prognostic model (Lille model) to identify candidates early on for alternative therapies. Three hundred twenty patients with AH prospectively treated by corticosteroids were included in the development cohort and 118 in its validation. Baseline data and a change in bilirubin at day 7 were tested. The model was generated by logistic regression. The model combining six reproducible variables (age, renal insufficiency, albumin, prothrombin time, bilirubin, and evolution of bilirubin at day 7) was highly predictive of death at 6 months (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.000001). The area under the receiver operating characteristic (AUROC) curve of the Lille model was 0.89 \u00b1 0.02, higher than the Child-Pugh (0.62 \u00b1 0.04,<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.00001) or Maddrey scores (0.66 \u00b1 0.04,<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.00001). In the validation cohort, its AUROC was 0.85 \u00b1 0.04, still higher than the other models, including MELD (0.72 \u00b1 0.05,<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.01) and Glasgow scores (0.67 \u00b1 0.05,<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.0008). Patients above the ideal cutoff of 0.45 showed a marked decrease in 6-month survival as compared with others: 25% \u00b1 3.8% versus 85% \u00b1 2.5%,<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.0001. This cutoff was able to identify approximately 75% of the observed deaths.<\/jats:bold>\n                      <jats:bold>Conclusion:<\/jats:bold>\n                      <jats:bold>In the largest cohort to date of patients with severe AH, we demonstrate that the term \u201cnonresponder\u201d can now be extended to patients with a Lille score above 0.45, which corresponds to 40% of cases. Early identification of subjects with substantial risk of death according to the Lille model will improve management of patients suffering from severe AH and will aid in the design of future studies for alternative therapies. (Hepatology 2007.)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.21607","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T20:07:53Z","timestamp":1179950873000},"page":"1348-1354","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":638,"title":["The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids"],"prefix":"10.1097","volume":"45","author":[{"given":"Alexandre","family":"Louvet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Naveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle","family":"Abdelnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jos\u00e9","family":"Ramond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Fartoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Dharancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Texier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Serfaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Boleslawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Deltenre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Canva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Ren\u00e9","family":"Pruvot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241201","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial.","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"key":"R2-6-20241201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis.","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"R3-6-20241201","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-113-4-299","article-title":"Do corticosteroids reduce mortality from alcoholic hepatitis? A metaanalysis of the randomized trials.","volume":"113","author":"Imperiale","year":"1990","journal-title":"Ann Intern Med"},{"key":"R4-6-20241201","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves shortterm survival in severe acute alcoholic hepatitis: a doubleblind, placebocontrolled trial.","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"R5-6-20241201","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomised clinical trial.","volume":"44","author":"Phillips","year":"2006","journal-title":"J Hepatol"},{"key":"R6-6-20241201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJM199202203260802","article-title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis.","volume":"326","author":"Ramond","year":"1992","journal-title":"N Engl J Med"},{"key":"R7-6-20241201","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with endstage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R8-6-20241201","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2004.00703.x","article-title":"The survival benefit of liver transplantation.","volume":"5","author":"Merion","year":"2005","journal-title":"Am J Transplant"},{"key":"R9-6-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2003.50016","article-title":"Model for endstage liver disease (MELD) and allocation of donor livers.","volume":"124","author":"Wiesner","year":"2003","journal-title":"Gastroenterology"},{"key":"R10-6-20241201","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1053\/gast.1996.v110.pm8964410","article-title":"Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone.","volume":"110","author":"Mathurin","year":"1996","journal-title":"Gastroenterology"},{"key":"R11-6-20241201","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0168-8278(01)00289-6","article-title":"Corticosteroids improve shortterm survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.","volume":"36","author":"Mathurin","year":"2002","journal-title":"J Hepatol"},{"key":"R12-6-20241201","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.hep.2003.09.038","article-title":"Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone.","volume":"38","author":"Mathurin","year":"2003","journal-title":"Hepatology"},{"key":"R13-6-20241201","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis.","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"R14-6-20241201","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/hep.20475","article-title":"Lowgrade steatosis and major changes in portal flow as new prognostic factors in steroidtreated alcoholic hepatitis.","volume":"40","author":"Duvoux","year":"2004","journal-title":"Hepatology"},{"key":"R15-6-20241201","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2005.06.003","article-title":"Corticosteroids for alcoholic hepatitis: whats next?","volume":"43","author":"Mathurin","year":"2005","journal-title":"J Hepatol"},{"key":"R16-6-20241201","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hep.20503","article-title":"MELD accurately predicts mortality in patients with alcoholic hepatitis.","volume":"41","author":"Dunn","year":"2005","journal-title":"Hepatology"},{"key":"R17-6-20241201","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gut.2004.050781","article-title":"Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score.","volume":"54","author":"Forrest","year":"2005","journal-title":"Gut"},{"key":"R18-6-20241201","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2004.12.022","article-title":"MELD score is a better prognostic model than ChildTurcottePugh score or discriminant function score in patients with alcoholic hepatitis.","volume":"42","author":"Srikureja","year":"2005","journal-title":"J Hepatol"},{"issue":"Suppl","key":"R19-6-20241201","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/lt.20601","article-title":"Is alcoholic hepatitis an indication for transplantation? Current management and outcomes.","volume":"11","author":"Mathurin","year":"2005","journal-title":"Liver Transpl"},{"key":"R20-6-20241201","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0168-8278(02)00086-7","article-title":"Is liver transplantation an appropriate treatment for acute alcoholic hepatitis?","volume":"36","author":"Lucey","year":"2002","journal-title":"J Hepatol"},{"key":"R21-6-20241201","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1530-0277.1988.tb00155.x","article-title":"Observer variation in assessment of liver biopsies of alcoholic patients.","volume":"12","author":"Bedossa","year":"1988","journal-title":"Alcohol Clin Exp Res"},{"key":"R23-6-20241201","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM198412063112302","article-title":"Shortterm and longterm survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone.","volume":"311","author":"Mendenhall","year":"1984","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21607","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200706000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T07:21:05Z","timestamp":1733037665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200706000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21607","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1088007.540970","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1088007.541304","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}